Journal article
Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
Leukemia research reports, Vol.16, p.100266
01/01/2021
DOI: 10.1016/j.lrr.2021.100266
PMCID: PMC8515291
PMID: 34692401
Abstract
B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibitor, has had success in some patients with high risk features. Venetoclax, a BCL-2 inhibitor, has primarily been used in the relapsed setting. We present a case of B PLL with deletion 17p and mutated TP53 treated with ibrutinib and venetoclax in the frontline setting which resulted in measurable/minimal residual disease negative remission for approximately three years.
Details
- Title: Subtitle
- Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
- Creators
- Maria Tariq Siddiqui - The University of Texas MD Anderson Cancer CenterAllyson Price - The University of Texas MD Anderson Cancer CenterAlessandra Ferrajoli - The University of Texas MD Anderson Cancer CenterGautam Borthakur - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- Leukemia research reports, Vol.16, p.100266
- DOI
- 10.1016/j.lrr.2021.100266
- PMID
- 34692401
- PMCID
- PMC8515291
- NLM abbreviation
- Leuk Res Rep
- ISSN
- 2213-0489
- eISSN
- 2213-0489
- Publisher
- Elsevier
- Number of pages
- 3
- Language
- English
- Date published
- 01/01/2021
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984848423802771
Metrics
5 Record Views